<DOC>
	<DOCNO>NCT01111162</DOCNO>
	<brief_summary>The overall goal study study influenza vaccine response HIV infect individual . Immunocompromised individual require special protection influenza , may respond appropriately standard kill vaccine . Patients receive H1N1 flu vaccine part standard care ask donate blood sample immunologic study . These study determine whether participant able produce appropriate antibody vaccine possibly identify predictor vaccine responsiveness . Our hypothesis vaccine responsiveness new H1N1 influenza vaccine compromise HIV infected patient .</brief_summary>
	<brief_title>H1N1 Influenza Vaccine Immunogenicity HIV-1 Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . A confirmed diagnosis HIV1 infection document licensed ELISA test kit confirm Western blot time prior study entry measurable HIV RNA viral load chart . Serum HIV1 antigen , plasma HIV1 RNA , second antibody test method ELISA acceptable alternative confirmatory test . 2 . &gt; 18 year 3 . Able understand comply plan study procedure . 4 . Provides write informed consent prior initiation study procedure . 5 . Subject 1 ) stable antiretroviral therapy outline DHHS treatment guideline HIV1 infected individual OR 2 ) antiretroviral therapy intend start treatment within next 30 day . 1 . Has know allergy egg component vaccine ( may include , limited : gelatin , formaldehyde , octoxinol chicken protein ) . 2 . Has history , opinion site investigator , severe reaction follow previous immunization seasonal TIV . 3 . Participation novel H1N1 influenza vaccine study past two year . 4 . Proven history , RTPCR , novel influenza H1N1 infection , , positive influenza diagnostic testing since June 2009 ( specificity H1N1 require ) prior study entry . 5 . Received live license vaccine within 4 week inactivate licensed vaccine within 1 week prior study entry . 6 . Scheduled administration live virus vaccine inactivate vaccine entry Day 21 visit . NOTE : Live inactivate vaccine expect administer study entry Day 21 visit exclude prevent potential interference immunogenicity responses confound safety result . Regular seasonal flu vaccination allow separated 7 day administration H1N1 vaccine . 7 . Received nonlicensed agent ( vaccine , drug , biologic , device , blood product , medication ) within 4 week prior vaccination study 8 . An acute illness and/or oral temperature great equal 100.0 degree F within 24 hour prior study entry . 9 . Use anticancer chemotherapy radiation therapy within precede 36 month study enrollment , immunosuppression result underlie illness treatment ( HIV1 infection ) . 10 . Active neoplastic disease ( exclude nonmelanoma skin cancer , HPVrelated cervical dysplasia , CIN grade 1 , 2 3 ) . 11 . Long term use glucocorticoid , include oral parenteral prednisone equivalent ( 2.0 mg/kg per day 20 mg total dose ) 2 consecutive week ( 2 week total ) past 3 month , highdose inhaled steroid ( &gt; 800 mcg/day beclomethasone dipropionate equivalent ) within past 3 month ( nasal topical steroid allow ) . 12 . Received immunoglobulin blood product 13 . Current diagnosis uncontrolled major psychiatric disorder . 14 . History GuillainBarr√© Syndrome subject subject 's family ( parent , sibling , half sibling , child ) . 15 . Any condition would , opinion site investigator , place subject unacceptable risk injury render subject unable meet requirement protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>H1N1 vaccination</keyword>
	<keyword>HIV infect individual</keyword>
</DOC>